Sildenafil citrate linked to increased chorodial thickness

Article

phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness ? an associated risk factor for central serous chorioretinopathy

A study published in Retina shows the phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness – an associated risk factor for central serous chorioretinopathy.

Dr Susham K. Vance et al., LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, USA, conducted a prospective, interventional study involving the administration of 100 mg of sildenafil citrate to 8 subjects with no previous ocular history. Enhanced depth imaging spectral-domain optical coherence tomography was used to measure choroidal thickness in both eyes at 1-hour and 3-hour intervals after ingestion.

The findings demonstrated that the mean chorodial thickness had increased by 12.3% from 334 μm to 375 μm after 1-hour. The mean choroidal thickness was 11.6% thicker than baseline at the 3-hour interval. No significant changes were noted in choroidal thickness between the 1-hour and 3-hour intervals.

The results were related to previous studies of phosphodiesterase-5 inhibitors and central serous chorioretinopathy. Sildenafil citrate increases choroidal thickness both 1-hour and 3-hours after administration.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.